Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Diabetes Trials Could Include Hypoglycemia As Patient-Reported Outcome

Executive Summary

FDA, industry and patient advocates all want studies to move beyond HbA1c, but still need to develop common thresholds and definitions to support patient-reported outcomes in diabetes drug development.

Advertisement

Related Content

FDA Safety Meetings: Outpatient Drugs, Hypoglycemia Getting Limelight
Quality-Of-Life, Emotional Well-Being Becoming Highly Utilized PROs In Diabetes Trials
Diabetes Trials Tend To Eschew Patient-Reported Outcomes
Diabetes Outcomes Trial Requirement Looks 'Increasingly Wise' – FDA’s Temple
Diabetes Drug Safety Might Be Best Assessed With Real-World Data
Will CV Verdicts For Onglyza, Nesina Cause FDA To Change Its Tune On Antidiabetic Safety?

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

PS119031

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel